{"organizations": [], "uuid": "5d3ae2364df3ce1bda470e3c1b1809d0f8d43771", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-zynerba-pharmaceuticals-initiates/brief-zynerba-pharmaceuticals-initiates-open-label-phase-2-trial-of-zyn002-in-developmental-and-epileptic-encephalopathies-idUSASC09VDH", "country": "US", "domain_rank": 408, "title": "BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE)", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-10T14:44:00.000+03:00", "replies_count": 0, "uuid": "5d3ae2364df3ce1bda470e3c1b1809d0f8d43771"}, "author": "", "url": "https://www.reuters.com/article/brief-zynerba-pharmaceuticals-initiates/brief-zynerba-pharmaceuticals-initiates-open-label-phase-2-trial-of-zyn002-in-developmental-and-epileptic-encephalopathies-idUSASC09VDH", "ord_in_thread": 0, "title": "BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE)", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "zynerba pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 10, 2018 / 11:47 AM / Updated 8 minutes ago BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE) Reuters Staff \nApril 10 (Reuters) - Zynerba Pharmaceuticals Inc: \n* ZYNERBA PHARMACEUTICALS INITIATES OPEN-LABEL PHASE 2 TRIAL OF ZYN002 IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEE) \n* EXPECTS TO REPORT TOPLINE RESULTS FROM PHASE 2 BELIEVE 1 CLINICAL TRIAL IN 2019 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-10T14:44:00.000+03:00", "crawled": "2018-04-10T15:06:55.020+03:00", "highlightTitle": ""}